Journal of Diabetes Research / 2015 / Article / Fig 1

Review Article

The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A “Me Too” or “the Special One” Antidiabetic Class?

Figure 1

Antidiabetic insulin-dependent and insulin-independent effects of GLP-1 on metabolic tissues, which are potentiated by inhibition of dipeptidyl peptidase-4, thus improving the glycaemic, insulinemic, and lipidic profile and the progression of the disease.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.